Q&A: Ken Song details RayzeBio’s path from Series A to IPO in 3 years, taking a down round and being disciplined
Ken Song almost never got into radiopharmaceuticals. But after back-to-back phone calls from venture capital leaders at Versant and venBio in March 2020, the repeat life sciences CEO took a deep dive into the field, which at that point was outside the radar of most people in drug development.
Those calls worked, and Song would go on to lead RayzeBio, a Phase III oncology company bought by Bristol Myers Squibb in December for $4.1 billion. Blink too quickly, and pieces of the RayzeBio story could easily be missed. The company went from Series A to Series B in three months. Over 90 days, the 120-employee operation also went from IPO to acquisition.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
